Welcome to our dedicated page for Kintara Therapeutics SEC filings (Ticker: KTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kintara Therapeutics Inc. (KTRA) filings document material-event disclosures for the issuer appearing in recent SEC records as TuHURA Biosciences, Inc. The record includes 8-K reports covering securities purchase agreements, private placements of common stock and warrants, warrant amendments, capital-structure terms, and operating results or corporate updates.
Additional disclosure categories include shareholder voting matters, governance matters, risk factors, material agreements, and financial-condition reporting. The filings also document the common-stock and warrant economics used in TuHURA's financing activity and amendments affecting warrants issued by a predecessor in a 2024 private placement of convertible notes.
TuHURA Biosciences, Inc. reports that it has advanced its previously announced private placement by securing immediate purchases of approximately $3.2 million from certain investors who had deferred part of their commitment. These investors were originally obligated to buy a remaining portion of a $3.7 million final tranche under a June 2, 2025 securities purchase agreement tied to a larger $12.6 million offering of common stock and warrants.
In return for accelerating the purchase of this final tranche amount, TuHURA agreed to amend existing warrants issued in a 2024 private placement of convertible notes. The company extended the expiration dates of warrants to purchase an aggregate of 1.5 million shares of common stock, moving their expiry out to December 31, 2030. The detailed terms are set out in the final closing and warrant amendment agreements referenced in the report.
KP Biotech Group LLC reported beneficial ownership of 447,232 shares of TuHURA Biosciences, Inc. common stock, representing 0.9% of the outstanding class. The filing states these shares confer sole voting and sole dispositive power over all 447,232 shares and that the stake was not acquired to influence control of the issuer. The percent ownership is calculated using an outstanding share count of 50,046,926 shares reported by the issuer. The filing is a Schedule 13G amendment and affirms the position is below the 5% ownership threshold that would trigger more extensive disclosure.
TuHURA Biosciences, Inc. reported that CA Patel F&F Investments, LLC beneficially owned 447,232 shares of the companys common stock as of June 12, 2025. That holding represents 0.9% of the outstanding class, calculated using 50,046,926 shares reported by the issuer as outstanding on August 11, 2025. The filing states the reporting person has sole voting and dispositive power over all 447,232 shares and that the shares were not acquired to influence control of the company.
The Schedule 13G/A provides the filers business address in Tampa, Florida, and is signed by Adam Baals as Manager of CA Patel F&F Investments, LLC on August 14, 2025.
TuHURA Biosciences, Inc. filed a current report to furnish a press release that outlines its financial results for the three months ended June 30, 2025 and provides a corporate update. The press release, dated August 14, 2025, is included as Exhibit 99.1 and is incorporated by reference into the report on a furnished, not filed, basis under securities laws. TuHURA’s common stock, with a par value of $0.001 per share, trades on the Nasdaq Capital Market under the symbol HURA.
TuHURA Biosciences completed the acquisition of Kineta, Inc. on June 30, 2025 under the Agreement and Plan of Merger dated December 11, 2024, as amended May 5, 2025. The transaction was structured as a two-step series of mergers: Merger Sub I merged into Kineta (the Surviving Entity), which then merged into Merger Sub II, with Merger Sub II surviving.
This Form 8-K/A amends TuHURA’s original June 30, 2025 report to furnish Item 9.01 financial disclosures. The amendment attaches Kineta’s unaudited consolidated financial statements as of March 31, 2025 and December 31, 2024 as Exhibit 99.1 and provides unaudited pro forma condensed combined financial information for TuHURA as Exhibit 99.2, including a pro forma balance sheet and statements of operations on the noted dates and periods. The filing notes substantially the same financial statements were previously included in TuHURA’s Form S-4, declared effective May 14, 2025. The amendment is signed by CFO Dan Dearborn.